Sign in
CompletedNo phase

Theranostic Guided Riboflavin/UV-A Corneal Cross-linking

Key facts

Who runs it
Regensight
Where
Italy3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
50 people enrolled
Started
27 Apr 2022
Ended
26 Jan 2024
Type of study
Interventional
Treatments tested
  • Riboflavin/UV-A corneal cross-linking
Record updated
11 February 2025

Who can take part

Age
18 years to 40 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • criteria for inclusion in the clinical trial are those currently referred to as the golden standard for the treatment of corneal cross-linking. The criterion to determine progression of keratoconus is based on providing at least one of the following evidences:
  • at least two Placido disk corneal topography measurements showing at least +1.00 D steepening of the Kmax value in the last year or longer interval period
  • at least two manifest refraction measurements showing at least -0.50 D change in spherical equivalent refraction in the last year or longer interval period
  • at least two central corneal thickness (CCT) measurements showing at least -10 µm change in in the last year or longer interval period

Who cannot take part

  • Concomitant eye diseases
  • History of herpetic keratitis
  • Inflammatory eye diseases
  • Anterior corneal curvature steeper than 63 D
  • Corneal thickness thinner than 400 µm
  • Corneal scarring
  • Descemetocele
  • Glaucoma
  • Cataract
  • Nistagmus
  • Pregnancy
  • Breast feeding

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a clinical study consisting of a study arm to validate accuracy and precision of the combined use of theranostic imaging biomarkers, riboflavin score and theranostic score, to assess and predict efficacy of corneal cross-linking in flattening the corneal topography Kmax value at 12-months postoperatively. The objective of the study is to assess the performance of the theranostic software module (Research Use Only) of a CE marked (CE1936) UV-A medical device, C4V CHROMO4VIS™, in order to validate its use for theranostic-guided corneal cross-linking treatment of keratoconus and corneal ectasia. The study hypothesis is that theranostic-guided riboflavin/UV-A corneal cross-linking with the C4V CHROMO4VIS™ system is safe and can estimate treatment efficacy during operation, regardless of treatment protocol, i.e., either with or without epithelial removal.

The group in the trial

  • Riboflavin/UV-A corneal cross-linking monitored by theranostic software moduleTreatment being tested

    One study arm receiving riboflavin/UV-A corneal cross-linking with either standard, epi-off, or transepithelial, epi-on, treatment protocol. Only one eye of each participant is designated as the study eye.

    Treatment: Riboflavin/UV-A corneal cross-linking

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Theranostic Guided Riboflavin/UV-A Corneal Cross-linking for Treatment of Keratoconus
Publications
Record updated
11 February 2025